Phaseline

Companies › A&G Pharmaceutical

A&G Pharmaceutical: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
AG-01
anti-Progranulin/GP88 monoclonal antibody
PGRNPhase 1Triple Negative Breast CancerNov 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05627960AG-01Phase 1Triple Negative Breast CancerOncologyNov 2026

Targets

PGRN (1)

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.